Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib.

Anh Thu VuLara AkingunsadeKonstantin HofferCordula PetersenChristian Stephan BetzKai RothkammThorsten RieckmannLara BussmannMalte Kriegs

Published in: Head & neck (2022)

The results demonstrate potential benefit of SFK inhibition in HNSCC but they also highlight challenges due to non-specificities of the different drugs.

Keyphrases

tyrosine kinase
cancer therapy
protein kinase
chronic myeloid leukemia
risk assessment
drug delivery
climate change